Niketa C Shah, MD
Associate Professor Adjunct; Director,Pediatric Cellular Therapy Program, Pediatric Hematology & Oncology; Director, Pediatric Bone Marrow Transplant Program
Research & Publications
Biography
News
Coauthors
Selected Publications
- Can defibrotide prophylaxis prevent sinusoidal obstruction syndrome following haematopoietic stem-cell transplantation?Shah N, Shenoy S. Can defibrotide prophylaxis prevent sinusoidal obstruction syndrome following haematopoietic stem-cell transplantation? The Lancet Haematology 2023, 10: e309-e311. PMID: 37001535, DOI: 10.1016/s2352-3026(23)00065-0.
- 391 Clinical Outcomes and Long-Term Follow-up of Children with Mixed Myeloid Chimerism Following Hematopoietic Cell Transplantation (HCT) for Sickle Cell Disease (SCD)Guilcher G, Dalal S, Suresh T, Yelamali A, Aljayyousi H, Bhatia M, Haight A, Khandelwal P, Khoury R, Lafay Q, Mandava M, Nickel R, Ngwube A, Rangarajan H, Shah N, Stenger E, Yelamanchili N, Shenoy S. 391 Clinical Outcomes and Long-Term Follow-up of Children with Mixed Myeloid Chimerism Following Hematopoietic Cell Transplantation (HCT) for Sickle Cell Disease (SCD). Transplantation And Cellular Therapy 2023, 29: s296-s297. DOI: 10.1016/s2666-6367(23)00460-8.
- Role of abatacept in the prevention of graft-versus-host disease: current perspectivesNgwube A, Rangarajan H, Shah N. Role of abatacept in the prevention of graft-versus-host disease: current perspectives. Therapeutic Advances In Hematology 2023, 14: 20406207231152644. PMCID: PMC9943961, DOI: 10.1177/20406207231152644.
- Role of abatacept in the prevention of graft-versus-host disease: current perspectivesNgwube A, Rangarajan H, Shah N. Role of abatacept in the prevention of graft-versus-host disease: current perspectives. Therapeutic Advances In Hematology 2023, 14: 20406207231152644. PMID: 36845849, PMCID: PMC9943961, DOI: 10.1177/20406207231152644.
- The Use of Extracorporeal Membrane Oxygenation As a Bridge to Bone Marrow Transplantation in a Patient With High-risk Acute Myeloid Leukemia.Nader M, Bonde P, Massaro S, Giuliano JS, Shah N. The Use of Extracorporeal Membrane Oxygenation As a Bridge to Bone Marrow Transplantation in a Patient With High-risk Acute Myeloid Leukemia. Journal Of Pediatric Hematology/oncology 2022 PMID: 36219701, DOI: 10.1097/MPH.0000000000002567.
- Hematopoietic Cell Transplantation for Congenital Dyserythropoietic Anemia: A Report from the Pediatric Transplant and Cellular Therapy ConsortiumRangarajan HG, Stanek JR, Abdel-Azim H, Modi A, Haight A, McKinney CM, McKeone DJ, Buchbinder DK, Katsanis E, Abusin GA, Ahmed I, Law J, Silva JG, Mallhi KK, Burroughs LM, Shah N, Shaw PJ, Greiner R, Shenoy S, Pulsipher MA, Abu-Arja R. Hematopoietic Cell Transplantation for Congenital Dyserythropoietic Anemia: A Report from the Pediatric Transplant and Cellular Therapy Consortium. Transplantation And Cellular Therapy 2022, 28: 329.e1-329.e9. PMID: 35288346, DOI: 10.1016/j.jtct.2022.03.007.
- 159 Relapse Risk for B-ALL Patients By Pre-Hematopoietic Cell Transplantation (HCT) Next-Generation Sequencing (NGS-MRD): An Interim Analysis of Observational Arm Subjects on Pediatric Transplantation and Cellular Therapy Consortium (PTCTC) ONC1701Quigg T, Skiles J, Keating A, Mahadeo K, Salzberg D, Madden L, Phelan R, Lalefar N, Caywood E, Hanna R, Bhatt S, Stefanski H, Horn B, Oshrine B, Higham C, Duffner U, Chewning J, Law J, Shah N, Huo J, Lehmann L, Ahmed I, Pulsipher M, Abdel-Azim H. 159 Relapse Risk for B-ALL Patients By Pre-Hematopoietic Cell Transplantation (HCT) Next-Generation Sequencing (NGS-MRD): An Interim Analysis of Observational Arm Subjects on Pediatric Transplantation and Cellular Therapy Consortium (PTCTC) ONC1701. Transplantation And Cellular Therapy 2022, 28: s130-s131. DOI: 10.1016/s2666-6367(22)00320-7.
- Post-transplant CD34+ selected stem cell boost as an intervention for declining mixed chimerism following reduced intensity conditioning allogeneic stem cell transplant in children and young adults with sickle cell disease: A case seriesNgwube A, Franay C, Shah N. Post-transplant CD34+ selected stem cell boost as an intervention for declining mixed chimerism following reduced intensity conditioning allogeneic stem cell transplant in children and young adults with sickle cell disease: A case series. Pediatric Hematology And Oncology 2022, 39: 475-480. PMID: 35147476, DOI: 10.1080/08880018.2021.2013369.
- Granulocyte Colony-Stimulating Factor Is Safe and Well Tolerated following Allogeneic Transplantation in Patients with Sickle Cell DiseaseShah NC, Bhoopatiraju S, Abraham A, Anderson E, Andreansky M, Bhatia M, Chaudhury S, Cuvelier GDE, Godder K, Grimley M, Hale G, Kamani N, Jacobsohn D, Ngwube A, Gilman AL, Skiles J, Yu LC, Shenoy S. Granulocyte Colony-Stimulating Factor Is Safe and Well Tolerated following Allogeneic Transplantation in Patients with Sickle Cell Disease. Transplantation And Cellular Therapy 2021, 28: 174.e1-174.e5. PMID: 34958973, DOI: 10.1016/j.jtct.2021.12.016.
- Evidence-Based Minireview: In young children with severe sickle cell disease, do the benefits of HLA-identical sibling donor HCT outweigh the risks?Shah N, Krishnamurti L. Evidence-Based Minireview: In young children with severe sickle cell disease, do the benefits of HLA-identical sibling donor HCT outweigh the risks? Hematology 2021, 2021: 190-195. PMID: 34889371, PMCID: PMC8791135, DOI: 10.1182/hematology.2021000322.
- Bone marrow transplant using fludarabine‐based reduced intensity conditioning regimen with in vivo T cell depletion in patients with Fanconi anemiaGorfinkel L, Demsky C, Pashankar F, Kupfer G, Shah NC. Bone marrow transplant using fludarabine‐based reduced intensity conditioning regimen with in vivo T cell depletion in patients with Fanconi anemia. Pediatric Transplantation 2021, 25: e14009. PMID: 33755277, DOI: 10.1111/petr.14009.
- Congenital dyserythropoietic anemia type I: First report from the Congenital Dyserythropoietic Anemia Registry of North America (CDAR)Niss O, Lorsbach R, Berger M, Chonat S, McLemore M, Buchbinder D, McCavit T, Shaffer L, Simpson J, Schwartz J, Meznarich J, Emberesh M, Seu K, Zhang W, Kalfa T, Husami A, Kalfa T, Lorsbach R, Lutzko C, Nelson A, Niss O, Quinn C, Seu K, Zhang W, Chonat S, Buchbinder D, Johnson C, McCavit T, Shaffer L, Rothman J, Gupta S, Toscano M, Forouhar M, Gidvani-Diaz V, Ball J, Roach G, Wagner K, Milanovich S, Boyer J, Chawla J, Smith C, Lee A, Simpson J, Schwartz J, Radulescu V, Abajas Y, Ritchey A, Meznarich J, Underhill H, Ravindranath Y, McLemore M, Shah N. Congenital dyserythropoietic anemia type I: First report from the Congenital Dyserythropoietic Anemia Registry of North America (CDAR). Blood Cells Molecules And Diseases 2020, 87: 102534. PMID: 33401150, PMCID: PMC8809105, DOI: 10.1016/j.bcmd.2020.102534.
- Granulocyte Colony-Stimulating Factor Is Safe and Well Tolerated Following Allogeneic Transplantation in Patients with Sickle Cell DiseaseShah N, Bhoopatiraju S, Abraham A, Anderson E, Andreansky M, Bhatia M, Chaudhury S, Cuvelier G, Godder K, Grimley M, Hale G, Kamani N, Jacobsohn D, Ngwube A, Skiles J, Yu L, Shenoy S. Granulocyte Colony-Stimulating Factor Is Safe and Well Tolerated Following Allogeneic Transplantation in Patients with Sickle Cell Disease. Blood 2020, 136: 33-33. DOI: 10.1182/blood-2020-142696.
- Abatacept is effective as GVHD prophylaxis in unrelated donor stem cell transplantation for children with severe sickle cell disease.Ngwube A, Shah N, Godder K, Jacobsohn D, Hulbert ML, Shenoy S. Abatacept is effective as GVHD prophylaxis in unrelated donor stem cell transplantation for children with severe sickle cell disease. Blood Advances 2020, 4: 3894-3899. PMID: 32813873, PMCID: PMC7448594, DOI: 10.1182/bloodadvances.2020002236.
- Low toxicity and favorable overall survival in relapsed/refractory B-ALL following CAR T cells and CD34-selected T-cell depleted allogeneic hematopoietic cell transplantFabrizio VA, Kernan NA, Boulad F, Cancio M, Allen J, Higman M, Margossian SP, Mauguen A, Prockop S, Scaradavou A, Shah N, Spitzer B, Stieglitz E, Yeager N, O’Reilly R, Brentjens RJ, Jan Boelens J, Curran KJ. Low toxicity and favorable overall survival in relapsed/refractory B-ALL following CAR T cells and CD34-selected T-cell depleted allogeneic hematopoietic cell transplant. Bone Marrow Transplantation 2020, 55: 2160-2169. PMID: 32390002, PMCID: PMC7606268, DOI: 10.1038/s41409-020-0926-1.
- Gene therapy in sickle cell disease: Possible utility and impactCurtis SA, Shah NC. Gene therapy in sickle cell disease: Possible utility and impact. Cleveland Clinic Journal Of Medicine 2020, 87: 28-29. PMID: 31990652, DOI: 10.3949/ccjm.87a.19124.
- Allogeneic CD34-Selected HSCT Following CAR T-Cells Is Associated with Low TRM and Favorable OS in Pediatric/Young Adult Patients with Relapsed/Refractory B-ALLFabrizio V, Boulad F, Cancio M, Higman M, Margossian S, Mauguen A, Prockop S, Scaradavou A, Shah N, Spitzer B, Yeager N, Kernan N, O'Reilly R, Boelens J, Curran K. Allogeneic CD34-Selected HSCT Following CAR T-Cells Is Associated with Low TRM and Favorable OS in Pediatric/Young Adult Patients with Relapsed/Refractory B-ALL. Blood 2019, 134: 4582-4582. DOI: 10.1182/blood-2019-121767.
- Abatacept Is Effective for Gvhd Prophylaxis after Unrelated Donor Stem Cell Transplantation (URD SCT) for Severe Sickle Cell Disease (SCD)Ngwube A, Shah N, Jacobsohn D, Dela Ziga E, Ziga E, Shenoy S. Abatacept Is Effective for Gvhd Prophylaxis after Unrelated Donor Stem Cell Transplantation (URD SCT) for Severe Sickle Cell Disease (SCD). Blood 2019, 134: 370-370. DOI: 10.1182/blood-2019-126405.
- GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemiaMehta RS, Holtan SG, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel DR, Alousi AM, Pidala J, Abdel-Azim H, Ahmed I, Aljurf M, Askar M, Auletta JJ, Bhatt V, Bredeson C, Chhabra S, Gadalla S, Gajewski J, Gale RP, Gergis U, Hematti P, Hildebrandt GC, Inamoto Y, Kitko C, Khandelwal P, MacMillan ML, Majhail N, Marks DI, Mehta P, Nishihori T, Olsson RF, Pawarode A, Diaz MA, Prestidge T, Qayed M, Rangarajan H, Ringden O, Saad A, Savani BN, Seo S, Shah A, Shah N, Schultz KR, Solh M, Spitzer T, Szer J, Teshima T, Verdonck LF, Williams KM, Wirk B, Wagner J, Yared JA, Weisdorf DJ. GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia. Blood Advances 2019, 3: 1441-1449. PMID: 31053571, PMCID: PMC6517657, DOI: 10.1182/bloodadvances.2018030171.
- Reduced‐toxicity allogeneic hematopoietic stem cell transplantation in congenital sideroblastic anemiaKim MH, Shah S, Bottomley SS, Shah NC. Reduced‐toxicity allogeneic hematopoietic stem cell transplantation in congenital sideroblastic anemia. Clinical Case Reports 2018, 6: 1841-1844. PMID: 30214775, PMCID: PMC6132150, DOI: 10.1002/ccr3.1667.
- CAR‐T cell manufacture: snatching victory when defeat is loomingGowda L, Shah NC. CAR‐T cell manufacture: snatching victory when defeat is looming. Transfusion 2018, 58: 1335-1337. PMID: 29949188, DOI: 10.1111/trf.14760.
- 106 Survival Trends after Allogeneic Hematopoietic Cell Transplant (HCT) in Children Less Than One-Year-Old (Infants)Parikh S, Ahn K, Sahr N, Zhu X, Abraham A, Auletta J, Chhabra S, Copelan E, Dvorak C, Fretham C, Gadalla S, Gale R, Gergis U, Heimatti P, Hildebrandt G, Keating A, Myers K, Savani B, Shah N, Pasquini M, Satwani P. 106 Survival Trends after Allogeneic Hematopoietic Cell Transplant (HCT) in Children Less Than One-Year-Old (Infants). Transplantation And Cellular Therapy 2018, 24: s116. DOI: 10.1016/j.bbmt.2017.12.032.
- 603 Evaluation of Utility of Computed Tomography Scanning in Pediatric Stem Cell Transplant Patients with Fever and NeutropeniaKim M, Adams R, Foote J, Shah N. 603 Evaluation of Utility of Computed Tomography Scanning in Pediatric Stem Cell Transplant Patients with Fever and Neutropenia. Transplantation And Cellular Therapy 2018, 24: s438. DOI: 10.1016/j.bbmt.2017.12.526.
- The Role of Thromboelastography in a Patient on Defibrotide Therapy with Abnormal Coagulation StudiesWigfield J, Salzberg D, Shah N, Miller H, Magee K, Beebe K, Adams R, Su L. The Role of Thromboelastography in a Patient on Defibrotide Therapy with Abnormal Coagulation Studies. Transplantation And Cellular Therapy 2016, 22: s295-s296. DOI: 10.1016/j.bbmt.2015.11.754.
- Impact of Conditioning Regimen in Allogeneic Stem Cell Transplant for Acute Myeloid Leukemia: The Phoenix Children's Hospital ExperienceShah N, Foote J, Magee K, Beebe K, Salzberg D, Douglas D, Adams R. Impact of Conditioning Regimen in Allogeneic Stem Cell Transplant for Acute Myeloid Leukemia: The Phoenix Children's Hospital Experience. Transplantation And Cellular Therapy 2016, 22: s260. DOI: 10.1016/j.bbmt.2015.11.691.
- Reduced Toxicity Allogeneic Transplant for Congenital Sideroblastic AnemiaKim M, Shah S, Adams R, Bottomley S, Shah N. Reduced Toxicity Allogeneic Transplant for Congenital Sideroblastic Anemia. Transplantation And Cellular Therapy 2016, 22: s252. DOI: 10.1016/j.bbmt.2015.11.677.
- Transplant Outcomes for Children with T Cell Acute Lymphoblastic Leukemia in Second Remission: A Report from the Center for International Blood and Marrow Transplant ResearchBurke M, Verneris M, Le Rademacher J, He W, Abdel-Azim H, Abraham A, Auletta J, Ayas M, Brown V, Cairo M, Chan K, Diaz Perez M, Dvorak C, Egeler R, Eldjerou L, Frangoul H, Guilcher G, Hayashi R, Ibrahim A, Kasow K, Leung W, Olsson R, Pulsipher M, Shah N, Shah N, Thiel E, Talano J, Kitko C. Transplant Outcomes for Children with T Cell Acute Lymphoblastic Leukemia in Second Remission: A Report from the Center for International Blood and Marrow Transplant Research. Transplantation And Cellular Therapy 2015, 21: 2154-2159. PMID: 26327632, PMCID: PMC4654112, DOI: 10.1016/j.bbmt.2015.08.023.
- Heparin-bonded catheters for prolonging the patency of central venous catheters in children.Shah PS, Shah N. Heparin-bonded catheters for prolonging the patency of central venous catheters in children. The Cochrane Database Of Systematic Reviews 2014, CD005983. PMID: 24569952, DOI: 10.1002/14651858.CD005983.pub3.
- Intrathecal Chemotherapy Post Hematopoietic Cell Transplantation for Prevention of Central Nervous System Relapse in Pediatric Acute LeukemiaMitchell R, Shah N, Lehrman R, Kobos R, Scaradavou A, Boulad F, Kernan N, O'Reilly R, Prockop S. Intrathecal Chemotherapy Post Hematopoietic Cell Transplantation for Prevention of Central Nervous System Relapse in Pediatric Acute Leukemia. Transplantation And Cellular Therapy 2014, 20: s84. DOI: 10.1016/j.bbmt.2013.12.104.
- Persistent human rhinovirus type C infection of the lower respiratory tract in a pediatric cord blood transplant recipientPathak A, Adams R, Shah N, Gustin K. Persistent human rhinovirus type C infection of the lower respiratory tract in a pediatric cord blood transplant recipient. Bone Marrow Transplantation 2012, 48: 747-748. PMID: 23165503, DOI: 10.1038/bmt.2012.226.
- Outcome and toxicity of chemotherapy for acute lymphoblastic leukemia in children with Down syndrome.Shah N, Al-Ahmari A, Al-Yamani A, Dupuis L, Stephens D, Hitzler J. Outcome and toxicity of chemotherapy for acute lymphoblastic leukemia in children with Down syndrome. Pediatric Blood & Cancer 2009, 52: 14-9. PMID: 18802938, DOI: 10.1002/pbc.21737.
- Diffuse intrinsic brainstem tumors in neonates. Report of two cases.Shah NC, Ray A, Bartels U, Rutka J, Bouffet E, Drake J, Hawkins CE, Huang A. Diffuse intrinsic brainstem tumors in neonates. Report of two cases. Journal Of Neurosurgery. Pediatrics 2008, 1: 382-5. PMID: 18447673, DOI: 10.3171/PED/2008/1/5/382.
- Late-appearing Philadelphia chromosome in childhood acute myeloid leukemia.Shah N, Leaker MT, Teshima I, Baruchel S, Abdelhaleem M, Ye CC. Late-appearing Philadelphia chromosome in childhood acute myeloid leukemia. Pediatric Blood & Cancer 2008, 50: 1052-3. PMID: 18213712, DOI: 10.1002/pbc.21317.
- Use of sentinel lymph node biopsy and high-dose interferon in pediatric patients with high-risk melanoma: the Hospital for Sick Children experience.Shah NC, Gerstle JT, Stuart M, Winter C, Pappo A. Use of sentinel lymph node biopsy and high-dose interferon in pediatric patients with high-risk melanoma: the Hospital for Sick Children experience. Journal Of Pediatric Hematology/oncology 2006, 28: 496-500. PMID: 16912589, DOI: 10.1097/01.mph.0000212973.28996.e4.
- Long-term results of an ultra low-dose cytarabine-based regimen for the treatment of acute megakaryoblastic leukaemia in children with Down syndrome.Al-Ahmari A, Shah N, Sung L, Zipursky A, Hitzler J. Long-term results of an ultra low-dose cytarabine-based regimen for the treatment of acute megakaryoblastic leukaemia in children with Down syndrome. British Journal Of Haematology 2006, 133: 646-8. PMID: 16704441, DOI: 10.1111/j.1365-2141.2006.06097.x.
- A 16-year-old girl with hypochromic microcytic anemia.Ye CC, Shah N, Edwards VD, Kirby-Allen M. A 16-year-old girl with hypochromic microcytic anemia. Archives Of Pathology & Laboratory Medicine 2005, 129: e199-201. PMID: 16253038, DOI: 10.1043/1543-2165(2005)129[e199:AYGWHM]2.0.CO;2.